The query "peptides for muscle" or "IGF-1 LR3" is useful for navigation but scientifically loose: it mixes IGF signaling, myostatin/activin pathway inhibitors, GH secretagogues, recovery peptides (BPC/TB), and lab RUO vials. Longeva hub does not sell a "mass-gain program". This page is a shelf map: who owns the muscle-growth commercial aisle, where hub wiki primers live, and where the research use only (RUO) boundary sits.
Educational only. Not medical advice, sports coaching, or human-use instructions.
Who owns which layer
| Layer | Where | What you get |
|---|---|---|
| Muscle growth RUO catalog | Regena · muscle growth | IGF-1 LR3, ACE-083, bimagrumab (BYM338) as research samples + COA |
| Deep catalog guide | Regena IGF / myostatin shelf | Molecule table, LOT/COA, no "best for mass" ranking |
| IGF-1 LR3 pillar (hub) | molecule structure & signaling | What models measured, not lifestyle promises |
| Myostatin pathway (hub) | ACE-083, bimagrumab | Follistatin-Fc / anti-ActRII research context |
| GLP-1 / weight loss (different aisle) | weight-loss shelf, Incretin | Semaglutide ≠ IGF-1 LR3; different metabolic axis |
| Recovery / joints (different aisle) | Regena BPC/TB | Connective-tissue repair, not hypertrophy shelf |
| GH secretagogues (adjacent cluster) | Evity · MK-677, ipamorelin, CJC-1295 | GH axis; does not replace IGF/myostatin shelf |
Regena is the canonical owner of muscle-growth / IGF / myostatin SKUs in our network (tentative governance; see brand matrix case 4). Hub stays editorial + navigation.
RUO framing
- A RUO vial carries INN and fill weight; COA describes batch analytics, not sports outcomes.
- In vitro and animal-model data do not transfer to dosing outside the lab protocol.
- "Hypertrophy" in marketing describes the search topic, not a verified vial effect.
Brand chooser: buy peptides · pick a brand.
Hub wiki (reference, no buy CTA)
- IGF-1 LR3 · ACE-083 · Bimagrumab
- hub PDP IGF-1 LR3 (neutral reference; buy on Regena)
Longeva hub · navigational only · does not replace a lab protocol.